Stable, charge-neutral antisense morpholino oligonucleotides tailored for splice-switching, translation blocking, delivery optimization, and advanced RNA-targeting research workflows.
Morpholino antisense oligonucleotides replace the natural ribose-phosphate backbone with morpholine rings linked by phosphorodiamidate bonds. This charge-neutral, nuclease-resistant chemistry is useful for RNA-targeting applications where researchers need splice modulation or translation blocking without RNase H-mediated RNA degradation.
Configured around your target sequence, application, delivery method, scale, and QC expectations.
10–40 bases, with 20–25 bases common for many targets.
5′, 3′, and internal labels using spacer or linker strategies.
MS identity confirmation, analytical HPLC, and optional advanced testing.
Designed for projects that require stable, synthetic antisense constructs with a steric-blocking mechanism.
Exon skipping, splice correction, splice-site blocking, and RNA-processing studies.
AUG/start-site targeting and 5′ UTR interference workflows.
CPP-PMO, peptide-PMO, lipid-PMO, and labeled PMO uptake studies.
Positioning: PMOs are RNase H-independent steric-blocking antisense oligos rather than RNA-cleaving gapmer-style ASOs.
Project fit: useful for developmental biology, cell delivery research, target validation, splice modulation, and translation-blocking experiments.
Thiomorpholino oligonucleotides (TMOs) are advanced morpholino analogs that replace the phosphorodiamidate linkage found in traditional PMOs with a thiophosphoramidate backbone. This chemistry provides greater synthetic flexibility, broader modification compatibility, and stronger RNA targeting potential for selected antisense applications [1].
Unlike conventional PMOs, TMOs can be synthesized using standard phosphoramidite chemistry, allowing integration of broader antisense architectures and mixed-modification strategies.
Thiophosphoramidate chemistry may improve hybridization strength to target RNA sequences, potentially increasing exon-skipping and gene-regulation efficiency.
Published studies suggest TMOs demonstrate strong resistance to nuclease degradation [1], helping prolong biological activity in experimental systems.
TMO systems have been investigated for exon skipping in Duchenne Muscular Dystrophy [2], Marfan Syndrome, TUG1 RNA regulation, and allele-selective FUS knockdown workflows.
Potency observations: Published reports describe strong exon 23 skipping potency for TMOs at lower concentrations [2] compared to PMOs and several alternative antisense chemistries.
Selective targeting: TMO gapmer systems have demonstrated higher allele-selective knockdown of FUS gene targets [3] compared with certain MOE-modified oligonucleotide approaches.
PMOs act through sequence-specific binding and physical obstruction. They can prevent spliceosome access, alter exon usage, or block ribosomal initiation without degrading the target RNA.
Define splice junction, regulatory element, AUG region, or accessible RNA segment based on the experimental objective.
The morpholino binds its complementary RNA region through base pairing while remaining resistant to nuclease attack.
The bound PMO physically blocks spliceosome or ribosome access, enabling splice-switching or translation-blocking research.
PMOs are useful when your program requires stable RNA binding, steric-blocking activity, and flexible delivery-enhancing conjugation strategies.
Exon skipping, splice correction, exon inclusion, splice-site blocking, and RNA-processing studies.
Targeting AUG/start codon regions and 5′ UTR elements to inhibit protein translation.
Frequently used in zebrafish, Xenopus, embryo microinjection, and early-stage functional studies.
Gene knockdown, target validation, pathway studies, and phenotype screening workflows.
CPP-PMO, lipid-PMO, PEG-PMO, and peptide-PMO uptake or biodistribution research.
Fluorescently labeled PMOs for localization, uptake, trafficking, and detection studies.
Specifications can be adjusted around target sequence, chemistry complexity, conjugation design, analytical requirements, and scale.
Bio-Synthesis supports PMO modification strategies for detection, solubility, uptake, targeting, and custom research workflows.
visibility, capture, coupling, and detection
PMOs can be configured with dyes, affinity tags, reactive handles, spacers, and cleavable linker systems.
uptake, targeting, and formulation support
Conjugation strategy can be selected around model system, delivery challenge, tissue/cell target, and downstream assay readout.
A structured workflow from target review through chemistry selection, PMO synthesis, purification, QC, and final delivery.
Start with a final PMO sequence, target RNA region, splice objective, translation-blocking site, or delivery challenge.
Review target, application, organism or cell system, design objective, and control strategy.
Select PMO/TMO format, labels, linkers, peptide/lipid conjugation, purification, and testing requirements.
Manufacture, purify, quantify, and verify the construct with MS, HPLC, and project-specific documentation.
Deliver lyophilized or buffered PMO material with requested format, labeling, and documentation.
Result: a custom PMO package aligned with your target sequence, application, delivery strategy, purification level, and QC documentation needs.
PMO deliverables can be configured for routine research, development support, or scale-up programs.
Need help before quoting?
Explore connected services for PMO delivery, conjugation, and antisense oligonucleotide development.
Include PMO sequence, target region, conjugation type, scale, purification, delivery format, and QC documentation needs.
Request Quote →
Trusted by biotech leaders worldwide for over 45+ years of delivering high quality, fast and scalable synthetic biology solutions.